US FDA sets its sights on delta-8 THC, firing warnings over health claims

The US Food and Drug Administration (FDA) has sent warning letters to five marketers of delta-8 THC products based on health claims the companies made.

The letters are the first sent by the FDA on delta-8 products. However, they largely mirror ones previously sent to companies that made health claims about CBD – indeed several of the companies involved were also warned about CBD claims.

And although health claims appear to be what triggered the warnings, the FDA took a much larger swipe at delta-8 products generally.

Read full article
I'm already a subscriber

Anthony Traurig

Senior advisor
Anthony is senior advisor to CannIntelligence, where he provides regulatory guidance on issues within the global cannabis sector. Having worked several years as a legal analyst at CannIntelligence, he continues to work on consultancy projects and contribute to regulatory products for the platform. Anthony has a BA in political science from North Carolina State University and a Juris Doctor from Charleston School of Law (South Carolina), and practised law for several years in the United States as a litigator.

Our Key Benefits

The global cannabis market is in an opaque regulatory environment that requires professionals to be on top of industry developments to make informed decisions and optimise their strategy.

CannIntelligence provides organisations with leading market and regulatory data analysis to anticipate and understand market developments globally and the impact of regulatory changes to the business.

  • Stay informed of any legal and market change in the sector that impacts your organisation
  • Maximise resources by getting market and legal data analysis daily in one place
  • Make smart decisions by understanding how the regulatory and market landscape evolves
  • Anticipate risks in your decisions by monitoring regulatory changes that impact your organization